use
commerci
laboratori
viracor
laboratori
lee
summit
mo
usa
detect
respiratori
virus
first
introduc
institut
mid
subject
six
month
yr
age
admit
holtz
children
hospit
jackson
health
system
miami
florida
octob
april
identifi
review
physician
bill
databas
univers
miami
miller
school
medicin
assign
diagnost
relat
group
number
respiratori
compromis
failur
liver
kidney
intestin
multiviscer
transplant
ensur
subject
identifi
jackson
health
system
databas
also
search
children
undergon
solid
organ
transplant
code
discharg
diagnos
bronchiol
viral
pneumonia
respiratori
tract
viral
infect
pneumon
retrospect
studi
approv
univers
miami
investig
review
board
inform
consent
waiv
identifi
medic
record
retrospect
review
subject
includ
success
tracheal
extub
h
immedi
transplant
surgeri
therebi
exclud
respiratori
failur
immedi
postop
period
subject
exclud
evid
increas
work
breath
tachypnea
retract
wheez
rale
hypoxemia
requir
oxygen
therapi
even
posit
antigen
cultur
viral
pcr
result
collect
data
includ
demograph
data
date
admiss
test
result
respiratori
sampl
test
confirm
exclud
respiratori
infect
includ
bacteri
andor
viral
cultur
result
presenc
symptom
fever
tachypnea
descript
respiratori
system
examin
presenc
hypoxemia
requir
oxygen
therapi
abnorm
chest
find
immunosuppress
administ
first
month
outcom
immunosuppress
regimen
differ
kidney
liver
intestin
transplant
overlap
recipi
receiv
steroid
induct
maintain
steroid
tacrolimu
prophylaxi
cmv
either
ganciclovir
valganciclovir
administ
three
month
recipi
receiv
pcp
prophylaxi
recipi
month
age
receiv
monthli
palivizumab
hospit
inpati
also
underw
weekli
screen
cmv
ebv
perform
blood
sampl
treat
physician
determin
type
sampl
test
would
use
evalu
symptomat
patient
lrtvi
diagnos
posit
virus
method
respiratori
sampl
np
ett
sampl
bal
clinic
symptom
describ
earlier
virus
detect
variabl
method
order
clinician
includ
antigen
detect
via
immunoflouresc
viral
cultur
viral
nucleic
acid
detect
via
viral
respiratori
panel
laboratori
lee
summit
mo
usa
perform
clinic
specimen
follow
virus
includ
molecular
assay
adenoviru
influenza
influenza
subtyp
influenza
subtyp
influenza
b
metapneumoviru
parainfluenza
rhinoviru
rsv
rsv
b
bacteri
superinfect
identifi
heavi
growth
least
one
organ
time
identif
viral
pathogen
death
follow
posit
test
without
resolut
symptom
record
mortal
associ
viru
incomplet
recoveri
defin
patient
discharg
new
oxygen
requir
medic
record
evalu
repres
hospit
admiss
associ
pcr
test
respiratori
sampl
admiss
exclud
subject
respiratori
insuffici
immedi
postop
period
nine
addit
subject
exclud
lower
respiratori
tract
symptomatolog
time
test
remain
symptomat
subject
posit
least
one
viru
remain
five
symptomat
subject
viru
identifi
bacteri
infect
confirm
demograph
characterist
clinic
condit
symptom
subject
viral
respiratori
infect
summar
tabl
median
age
subject
time
transplant
month
rang
time
present
month
rang
transplant
perform
decemb
februari
percent
studi
subject
receiv
intestin
graft
receiv
liver
graft
one
patient
receiv
multiviscer
transplant
combin
kidney
transplant
isol
kidney
transplant
recipi
admit
pneumonia
time
period
three
subject
develop
lrtvi
within
first
month
transplant
diagnos
one
six
month
diagnos
month
transplant
subject
receiv
steroid
induct
maintain
steroid
tacrolimu
one
liver
recipi
ten
intestin
recipi
also
receiv
addit
immunosuppress
induct
nine
thymoglobulin
two
daclizumab
one
rituximab
two
liver
recipi
nine
intestin
recipi
receiv
addit
immunosuppress
first
month
manag
acut
reject
thymoglobulin
rituximab
daclizumab
subject
identifi
viral
pathogen
rsv
identifi
five
antigen
detect
subsequ
confirm
viral
cultur
two
five
subject
evalu
virus
multiplex
rhinoviru
frequent
detect
viral
pathogen
identifi
subject
two
influenza
pneumocysti
respect
influenza
parainfluenza
account
four
case
three
case
respect
adenoviru
identifi
two
case
one
case
also
persist
posit
parainfluenza
type
final
one
case
metapneumoviru
season
distribut
respiratori
pathogen
shown
fig
human
rhinoviru
rsv
occur
year
round
parainfluenza
type
occur
late
spring
earli
summer
six
patient
becam
ill
initi
transplant
hospit
two
posit
diagnost
test
within
h
icu
admiss
suggest
harbor
viru
time
transplant
one
case
viru
appear
contract
intens
care
unit
three
becam
symptomat
hospit
ward
five
patient
becam
symptomat
ward
subsequ
hospit
remain
case
appear
contract
commun
three
patient
identifi
bacteri
superinfect
one
mycobacterium
two
pseudomona
overal
mortal
mortal
subject
pathogen
identifi
three
subject
succumb
due
respiratori
failur
relat
lrti
two
rsv
one
adenoviru
rsv
mortal
despit
attempt
decreas
immunosuppress
administr
palivizumab
two
patient
rhinoviru
one
rsv
prolong
complex
hospit
die
caus
one
patient
adenoviru
die
respiratori
failur
evid
adenoviru
time
death
follow
treatment
cidofovir
nine
patient
requir
oxygen
supplement
discharg
retrospect
studi
design
describ
distribut
clinic
signific
lrtvi
pediatr
solid
organ
transplant
popul
lung
transplant
recipi
rhinoviru
detect
subject
sole
identifi
pathogen
subject
similar
distribut
virus
report
immunocompet
children
hospit
period
viral
respiratori
infect
sever
diagnost
test
use
identifi
infecti
agent
includ
blood
cultur
viral
cultur
direct
fluoresc
antibodi
serolog
pcr
pneumococc
viru
detect
case
influenza
rsv
parainfluenza
virus
common
rhinoviru
studi
detect
cultur
inferior
detect
method
associ
infect
use
molecular
techniqu
symptomat
children
childcar
set
fairchok
et
al
recent
demonstr
rhinoviru
commonli
identifi
organ
furthermor
viru
account
greatest
number
febril
wheez
episod
highest
total
visit
healthcar
provid
difficulti
grow
rhinoviru
cultur
coupl
fact
rhinoviru
prefer
temperatur
led
previou
assumpt
rhinoviru
confin
infect
upper
airway
howev
either
nasopharyng
aspir
bal
sampl
patient
hospit
lower
respiratori
tract
diseas
assay
monoclon
antibodi
direct
fluoresc
antibodi
stain
rhinoviru
detect
subject
human
rhinoviru
demonstr
endobronchi
biopsi
taken
infant
persist
respiratori
symptom
situ
rna
hybrid
furthermor
subject
singl
viral
infect
declin
human
rhinoviru
viral
load
associ
clinic
improv
sever
studi
perform
adult
immunocompromis
patient
employ
molecular
test
among
adult
lung
transplant
recipi
respiratori
tract
infect
evalu
viral
pcr
viral
nucleic
acid
detect
case
rhinoviru
three
use
detect
virus
includ
human
rhinoviru
symptomat
patient
human
rhinoviru
viru
frequent
detect
bal
specimen
vu
et
al
recent
summar
studi
report
respiratori
infect
lung
transplant
recipi
account
sampl
distribut
viral
infect
vari
wide
depend
factor
whether
upper
lower
respiratori
infect
studi
number
virus
detect
sensit
molecular
methodolog
greater
number
virus
detect
molecular
method
coronaviru
rhinoviru
frequent
detect
limit
data
epidemiolog
viral
infect
pediatr
solid
organ
transplant
recipi
retrospect
review
identifi
pediatr
lung
transplant
recipi
experienc
respiratori
viral
infect
involv
either
upper
andor
lower
respiratori
tract
first
year
frequent
detect
viru
adenoviru
case
follow
rhinoviru
case
rsv
case
parainfluenza
viru
case
influenza
viru
enteroviru
author
attribut
incid
rhinoviru
infect
use
molecular
test
liu
et
al
identifi
younger
age
time
transplant
immunosuppress
regimen
independ
risk
factor
develop
respiratori
viral
infect
lung
transplant
recipi
appear
hold
true
abdomin
organ
transplant
recipi
jan
decemb
children
yr
age
underw
abdomin
organ
transplant
holtz
children
hospit
jackson
health
system
miami
florida
liver
transplant
intestin
transplant
recipi
account
organ
transplant
respect
kidney
recipi
account
transplant
among
abdomin
organ
transplant
lrti
intestin
recipi
receiv
greater
immunosuppress
part
via
higher
target
calcineurin
inhibitor
concentr
account
lrtvi
furthermor
children
less
year
age
time
transplant
account
abdomin
organ
transplant
lrtvi
signific
mortal
rsv
infect
observ
cohort
pohl
et
al
previous
describ
episod
rsv
infect
among
pediatr
liver
transplant
recipi
four
subject
histori
previou
lung
diseas
experienc
respiratori
failur
two
die
four
develop
infect
within
first
postop
month
contrast
among
kidney
transplant
recipi
five
develop
rsv
infect
youngest
month
transplant
death
present
studi
one
death
occur
subject
receiv
rituximab
steroid
hemolyt
anemia
second
occur
patient
like
infect
prior
surgeri
like
lrtvi
gener
younger
age
greater
immunosuppress
appear
risk
factor
seriou
rsv
diseas
sever
limit
present
studi
prospect
studi
patient
suggest
pcr
may
overli
sensit
virus
detect
produc
signific
diseas
previou
studi
viral
detect
yield
prospect
collect
specimen
asymptomat
patient
use
pcr
two
time
greater
cultur
four
time
greater
fluoresc
antibodi
detect
similarli
either
nasopharyng
aspir
bal
sampl
symptomat
hospit
patient
assay
monoclon
antibodi
direct
fluoresc
antibodi
stain
rhinoviru
detect
subject
current
studi
symptomat
patient
includ
bacteri
detect
one
symptomat
case
rhinoviru
detect
result
may
generaliz
transplant
popul
andor
transplant
center
popul
rel
young
therefor
immunolog
may
impact
suscept
infect
exposur
result
may
also
simpli
reflect
subject
exposur
viru
commun
unexpectedli
detect
signific
cmv
diseas
frequent
cite
common
caus
pneumon
transplant
popul
although
viral
respiratori
panel
includ
cmv
cmv
detect
shell
vial
assay
low
incid
cmv
pneumon
like
due
use
viral
prophylaxi
find
current
studi
contribut
limit
avail
data
epidemiolog
viral
lrti
immunocompromis
hospit
pediatr
patient
present
studi
pediatr
abdomin
transplant
recipi
symptom
lower
respiratori
tract
ill
evalu
multiplex
addit
common
diagnost
test
posit
least
one
viru
impli
use
significantli
improv
yield
clinic
sampl
immunocompromis
host
respiratori
symptom
rhinoviru
detect
symptomat
subject
associ
death
indic
rhinoviru
may
signific
caus
morbid
mortal
pediatr
abdomin
organ
transplant
recipi
studi
design
ttt
gem
acquir
analyz
data
draft
manuscript
ak
provid
addit
data
ak
iag
critic
review
final
manuscript
